This transparent model eliminates hidden markups, where costs might be artificially inflated before being passed to the plan sponsor, and removes the incentive for PBMs to prioritize higher-cost drugs
Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) anchor the portfolio, supported by Jardiance and the legacy diabetes drug Trulicity
[DOI] [PMC free article] [PubMed] [Google Scholar] 165.Schlichthaerle T., Strauss M.T., Schueder F., Auer A., Nijmeijer B., Kueblbeck M., Jimenez Sabinina V., Thevathasan J.V., Ries J., Ellenberg J., et al
81), so it will better solvate the Na+ and Cl ions
Physician 94 , 820827 (2016)
History of eating disorders was assessed with the question: Since the age of 16, which of the following, if any, has a doctor or health professional ever told you that you had? Responses were dichotomised to distinguish between those who responded an eating disorder and those who did not